{
  "source": "PA-Notification-Tarceva.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1104-14\nProgram Prior Authorization/Notification\nMedication Tarceva® (erlotinib)\nP&T Approval Date 8/2008, 6/2009, 6/2010, 9/2010, 12/2010, 9/2011, 8/2012, 7/2013,\n2/2014, 2/2015, 2/2016, 12/2016, 11/2017, 11/2018, 11/2019, 11/2020,\n11/2021, 11/2022, 11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nTarceva® (erlotinib) is a kinase inhibitor indicated for the treatment of patients with metastatic non-\nsmall cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon\n19 deletions or exon 21 (L858R) substitution mutations receiving first-line, maintenance, or second or\ngreater line treatment after progression following at least one prior chemotherapy regimen.1 Tarceva\nis also indicated as first-line treatment for locally advanced, unresectable, or metastatic pancreatic\ncancer in combination with gemcitabine.1\nIn addition, the National Cancer Comprehensive Network (NCCN) also recommends Tarceva for the\ntreatments of chordoma, brain, leptomeningeal, and spine metastases originating from NSCLC,\nrelapsed or stage IV kidney cancer with non-clear cell histology, NSCLC with known sensitizing\nEGFR mutations, and vulvar cancer.2\nThe safety and efficacy of Tarceva has not been established in patients with NSCLC whose tumors\nhave other EGFR mutations. Tarceva is not recommended for use in combination with platinum-\nbased chemotherapy.1\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of 19\nyears, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of ag",
    " of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Tarceva will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Pancreatic Cancer\n1. Initial Authorization\n© 2024 UnitedHealthcare Services, Inc.\n1\na. Tarceva will be approved based on all of the following criteria:\n(1) Diagnosis pancreatic cancer\n-AND-\n(2) Disease is one of the following:\n(a) Locally advanced\n(b) Unresectable\n(c) Metastatic\n-AND-\n(3) Used in combination with gemcitabine\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tarceva will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tarceva therapy\nAuthorization will be issued for 12 months.\nC. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Tarceva will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n(b) Disease is one of the following:\n(a) Recurrent\n(b) Advanced\n(c) Metastatic\n-AND-\n(c) One of the following:\ni. Tumors are positive for epidermal growth factor receptor (EGFR) exon\n19 deletions\n© 2024 UnitedHealthcare Services, Inc.\n2\nii. Tumors are positive for exon 21 (L858R) substitution mutations\niii. Tumors are positive for a known sensitizing EGFR mutation (e.g.,\nS768I, L861Q, G719X)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tarceva will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tarceva therapy\nAuthorization will be issued for 12 months.\nD. Chordoma\n1. Initial Authorization\na. Tarceva will be approved based on the following criterion:\n(1) Diagnosis of chordoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tarceva will be a",
    "oma\n1. Initial Authorization\na. Tarceva will be approved based on the following criterion:\n(1) Diagnosis of chordoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tarceva will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tarceva therapy\nAuthorization will be issued for 12 months.\nE. Kidney Cancer\n1. Initial Authorization\na. Tarceva will be approved based on both of the following criteria:\n(1) Both of the following:\n(a) Diagnosis of kidney cancer\n(b) Disease is stage IV or relapsed\n-AND-\n(2) Disease is of non-clear cell histology\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2024 UnitedHealthcare Services, Inc.\n3\na. Tarceva will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tarceva therapy\nAuthorization will be issued for 12 months.\nF. Central Nervous System (CNS) Cancers\n1. Initial Authorization\na. Tarceva will be approved based on both of the following criteria:\n(1) Diagnosis of brain, leptomeningeal, or spine metastases from NSCLC\n-AND-\n(2) One of the following:\n(a) Tumors are positive for epidermal growth factor receptor (EGFR) exon 19\ndeletions\n(b) Tumors are positive for exon 21 (L858R) substitution mutations\n(c) Tumors are positive for a known sensitizing EGFR mutation (e.g., S768I,\nL861Q, G719X)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tarceva will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tarceva therapy\nAuthorization will be issued for 12 months.\nG. Vulvar Cancer\n1. Initial Authorization\na. Tarceva will be approved based on the following criterion:\n(1) Diagnosis of vulvar cancer\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tarceva will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tarceva therapy\n© 2024 Un",
    "l be issued for 12 months.\n2. Reauthorization\na. Tarceva will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tarceva therapy\n© 2024 UnitedHealthcare Services, Inc.\n4\nAuthorization will be issued for 12 months.\nH. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Tarceva [package insert]. South San Francisco, CA: Genentech USA, Inc.; October 2016.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at NCCN\nDrugs and Biologics Compendium®. Accessed October 8, 2024.\nProgram Prior Authorization/Notification - Tarceva (erlotinib)\nChange Control\n2/2014 Clarified indications for and added coverage for kidney cancer.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n2/2015 Annual review. Removed coverage esophageal and esophagogastric\njunction cancers – NCCN no longer recommends. Added coverage for\nleptomeningeal metastases. Clarified kidney cancer criteria. Updated\nbackground and references.\n2/2016 Annual review. Revised formatting of criteria. Changed initial and\nreauthorization periods to 12 months. Updated references.\n12/2016 Annual review. Changed member to p",
    "ackground and references.\n2/2016 Annual review. Revised formatting of criteria. Changed initial and\nreauthorization periods to 12 months. Updated references.\n12/2016 Annual review. Changed member to patient in coverage criteria.\nSimplified coverage criteria for NSCLC and added coverage for\nNSCLC with a known sensitizing EGFR mutation (per NCCN).\nSimplified coverage criteria for kidney cancer (per NCCN). Added\ncoverage criteria for vulvar cancer (per NCCN). Updated background,\nformatting and references.\n11/2017 Annual review with no change to clinical coverage criteria. Updated\nreference.\n© 2024 UnitedHealthcare Services, Inc.\n5\n11/2018 Annual review. Updating background and criteria to align with NCCN\nrecommendations for the treatment of metastatic CNS cancer.\nRemoved “off-label” from NCCN Compendium supported indications.\nUpdated background and references.\n11/2019 Annual review. Added general NCCN recommendations for use\ncriteria. Updated reference.\n11/2020 Annual review. Minor change to kidney cancer section for clarity of\nintent. Added other EGFR sensitizing mutations to align with NSCLC\nsection. Updated references.\n11/2021 Annual review with no changes to clinical coverage criteria. Updated\nreferences.\n11/2022 Annual review. Added coverage of advanced NSCLC and updated\nexamples of known sensitizing EGFR mutations for NSCL and CNS\ncancers. Added leptomeningeal and spine metastases to background\nand CNS Cancers criteria. Updated reference and added state mandate\nfootnote.\n11/2023 Annual review with no changes to clinical coverage criteria. Updated\nreferences.\n11/2024 Annual review with no changes to clinical coverage criteria. Updated\nreferences.\n© 2024 UnitedHealthcare Services, Inc.\n6"
  ]
}